Skip to main content
Top
Published in: Strahlentherapie und Onkologie 8/2022

Open Access 13-03-2022 | Prostate Cancer | Original Article

Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy

Authors: Matthias Moll, David D’Andrea, Alexandru Zaharie, Bernhard Grubmüller, Christopher Paschen, Sonja Zehetmayer, Shahrokh F. Shariat, Joachim Widder, Gregor Goldner

Published in: Strahlentherapie und Onkologie | Issue 8/2022

Login to get access

Abstract

Purpose

Hypofractionated radiotherapy for prostate cancer is well established for definitive treatment, but not well defined in the postoperative setting. The purpose of this analysis was to assess oncologic outcomes and toxicity in a large cohort of patients treated with conventionally fractionated three-dimensional (3D) conformal radiotherapy (CF) and hypofractionated volumetric modulated arc therapy (HF) after radical prostatectomy.

Methods

Between 1994 and 2019, a total of 855 patients with prostate carcinoma were treated by postoperative radiotherapy using CF (total dose 65–72 Gy, single fraction 1.8–2 Gy) in 572 patients and HF (total dose 62.5–63.75 Gy, single fraction 2.5–2.55 Gy) in 283 patients. The association of treatment modality with biochemical control, overall survival (OS), and gastrointestinal (GI) and genitourinary (GU) toxicity was assessed using logistic and Cox regression analysis.

Results

There was no difference between the two modalities regarding biochemical control rates (77% versus 81%, respectively, for HF and CF at 24 months and 58% and 64% at 60 months; p = 0.20). OS estimates after 5 years: 95% versus 93% (p = 0.72). Patients undergoing HF had less frequent grade 2 or higher acute GI or GU side effects (p = 0.03 and p = 0.005, respectively). There were no differences in late GI side effects between modalities (hazard ratio 0.99). Median follow-up was 23 months for HF and 72 months for CF (p < 0.001).

Conclusion

For radiation therapy of resected prostate cancer, our analysis of this largest single-centre cohort (n = 283) treated with hypofractionation with advanced treatment techniques compared with conventional fractionation did not yield different outcomes in terms of biochemical control and toxicities. Prospective investigating of HF is merited.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cornford P et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282CrossRef Cornford P et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282CrossRef
3.
go back to reference Van den Broeck T, van den Bergh RCN, Arfi N (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer : a systematic review. Eur Urol 75:967–987CrossRef Van den Broeck T, van den Bergh RCN, Arfi N (2019) Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer : a systematic review. Eur Urol 75:967–987CrossRef
4.
go back to reference Kneebone A et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21:1331–1340CrossRef Kneebone A et al (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21:1331–1340CrossRef
5.
go back to reference Parker CC et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396:1413–1421CrossRef Parker CC et al (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396:1413–1421CrossRef
6.
go back to reference Yu JB (2017) Hypofractionated radiotherapy for prostate cancer: further evidence to tip the scales. J Clin Oncol 35:1867–1869CrossRef Yu JB (2017) Hypofractionated radiotherapy for prostate cancer: further evidence to tip the scales. J Clin Oncol 35:1867–1869CrossRef
7.
go back to reference Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060CrossRef Dearnaley D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060CrossRef
8.
go back to reference Sharfo AWM et al (2018) Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiother Oncol 128:349–356CrossRef Sharfo AWM et al (2018) Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiother Oncol 128:349–356CrossRef
9.
go back to reference Cuccia F et al (2018) Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res 10:5053–5060CrossRef Cuccia F et al (2018) Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res 10:5053–5060CrossRef
10.
go back to reference Barra S et al (2018) Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome. Cancer Manag Res 10:473–480CrossRef Barra S et al (2018) Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome. Cancer Manag Res 10:473–480CrossRef
11.
go back to reference Cozzarini C et al (2014) Higher-than-expected severe (grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66:1024–1030CrossRef Cozzarini C et al (2014) Higher-than-expected severe (grade 3–4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66:1024–1030CrossRef
12.
go back to reference Tramacere F et al (2018) Postoperative hypofractionated radiotherapy for prostate cancer. Anticancer Res 38:2951–2956PubMed Tramacere F et al (2018) Postoperative hypofractionated radiotherapy for prostate cancer. Anticancer Res 38:2951–2956PubMed
13.
go back to reference Kruser TJ et al (2011) Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 117:2629–2636CrossRef Kruser TJ et al (2011) Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 117:2629–2636CrossRef
15.
go back to reference Macchia G et al (2017) Hypofractionated postoperative IMRT in prostate carcinoma: a phase I/II study. Anticancer Res 37:5821–5828PubMed Macchia G et al (2017) Hypofractionated postoperative IMRT in prostate carcinoma: a phase I/II study. Anticancer Res 37:5821–5828PubMed
16.
go back to reference Bolla M et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef Bolla M et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef
17.
go back to reference Rana S, Cheng C (2014) Radiobiological impact of planning techniques for prostate cancer in terms of tumor control probability and normal tissue complication probability. Ann Med Health Sci Res 4:167CrossRef Rana S, Cheng C (2014) Radiobiological impact of planning techniques for prostate cancer in terms of tumor control probability and normal tissue complication probability. Ann Med Health Sci Res 4:167CrossRef
18.
go back to reference Roach M et al (2006) Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation therapy oncology group 9413 trial. Int J Radiat Oncol Biol Phys 66:647–653CrossRef Roach M et al (2006) Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the radiation therapy oncology group 9413 trial. Int J Radiat Oncol Biol Phys 66:647–653CrossRef
19.
go back to reference Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRef Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRef
20.
go back to reference Cookson MS et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the re. J Urol 177:540–545CrossRef Cookson MS et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the re. J Urol 177:540–545CrossRef
21.
go back to reference Hwang WL et al (2018) Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 4:1–8 Hwang WL et al (2018) Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 4:1–8
22.
go back to reference Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G (2011) A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80:1316–1322CrossRef Ost P, De Troyer B, Fonteyne V, Oosterlinck W, De Meerleer G (2011) A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80:1316–1322CrossRef
23.
go back to reference Katayama S et al (2014) Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS‑1 trial. Int J Radiat Oncol Biol Phys 90:926–933CrossRef Katayama S et al (2014) Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS‑1 trial. Int J Radiat Oncol Biol Phys 90:926–933CrossRef
24.
go back to reference Waldstein C, Dörr W, Pötter R, Widder J, Goldner G (2018) Postoperative radiotherapy for prostate cancer: morbidity of local-only or local-plus-pelvic radiotherapy. Strahlenther Onkol 194:23–30CrossRef Waldstein C, Dörr W, Pötter R, Widder J, Goldner G (2018) Postoperative radiotherapy for prostate cancer: morbidity of local-only or local-plus-pelvic radiotherapy. Strahlenther Onkol 194:23–30CrossRef
25.
go back to reference Murthy V et al (2020) Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother Oncol 145:71–80CrossRef Murthy V et al (2020) Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial. Radiother Oncol 145:71–80CrossRef
26.
go back to reference Sujenthiran A et al (2018) Treatment-related toxicity in men who received intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: a national population-based study. Radiother Oncol 128:357–363CrossRef Sujenthiran A et al (2018) Treatment-related toxicity in men who received intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: a national population-based study. Radiother Oncol 128:357–363CrossRef
Metadata
Title
Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy
Authors
Matthias Moll
David D’Andrea
Alexandru Zaharie
Bernhard Grubmüller
Christopher Paschen
Sonja Zehetmayer
Shahrokh F. Shariat
Joachim Widder
Gregor Goldner
Publication date
13-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 8/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-01909-2

Other articles of this Issue 8/2022

Strahlentherapie und Onkologie 8/2022 Go to the issue